 
      PDS Biotechnology has a growing pipeline of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, cervical cancer, anal cancer, prostate cancer, breast cancer and other cancers. PDS Biotechnologyâs lead product candidate PDS0101 demonstrated strong induction of the expected immune responses (e.g. antigen-specific CD8+ T-cell responses) without any observed dose-limiting toxicities in a completed Phase 1/2a clinical trial. Source
No articles found.
 
                  The Pennant Group, Inc. is a holding company of independent operating subsidiaries...
The Pennant Group, Inc. is a holding company of...
 
                  Sage Therapeutics is a biopharmaceutical company committed to developing novel the...
Sage Therapeutics is a biopharmaceutical compan...
 
                  Bioptimizers offers health and nutrition supplements.
Bioptimizers offers health and nutrition supple...
 
                  InflaRx (Nasdaq: IFRX) is a clinical-stage biopharmaceutical company focused on ap...
InflaRx (Nasdaq: IFRX) is a clinical-stage biop...
 
                  EyeGate is developing and commercializing products for treating diseases and disor...
EyeGate is developing and commercializing produ...
 
                  Phibro Animal Health Corporation is a leading global diversified animal health and...
Phibro Animal Health Corporation is a leading g...
 
                  Heat Biologics a biopharmaceutical company that develops immunotherapies with the ...
Heat Biologics a biopharmaceutical company that...
 
                  Inovio is bringing IMMUNO-INGENUITY⢠to life and is reshaping the future of trea...
Inovio is bringing IMMUNO-INGENUITY⢠to life ...
 
                  We are a biotechnology company developing novel immunotherapy treatments for cance...
We are a biotechnology company developing novel...
 
                  Synthorx is a biotechnology company focused on prolonging and improving the lives ...
Synthorx is a biotechnology company focused on ...
Join the National Investor Network and get the latest information with your interests in mind.